SCHEMBL418476

SCHEMBL418476

CN(C(=O)CCCSc1ccc(F)cc1)C1CCOc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.34
▸ HTT P42858 2/20 0.34
▸ XBP1 P17861 1/20 0.34
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CCR3 P51677 3/20 0.33
▸ HTR2A P28223 2/20 0.33
▸ HTR2C P28335 2/20 0.33
▸ PDE3B Q13370 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ ADRA1B P35368 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ APOL1 O14791 1/20 0.32
▸ MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL414286 0.91 ALDH1A1 (0.36) ALDH1A1NPC1RAB9ACCR3PDE3B
SCHEMBL419712 0.81 ALDH1A1 (0.57) ALDH1A1HTTXBP1RAB9AHTR2A
SCHEMBL12269707 0.71 GAA (0.41) ALDH1A1HTTXBP1RAB9A
SCHEMBL21798464 0.71 SSTR4 (0.40) ALDH1A1HTTXBP1RAB9A
SCHEMBL21798459 0.71 SSTR4 (0.40) ALDH1A1HTTXBP1RAB9A
SCHEMBL11035258 0.71 TRPM8 (0.41) ALDH1A1HTTXBP1TDP1KMT2A
SCHEMBL7505462 0.70 KMT2A (0.48) ALDH1A1HTTXBP1KMT2A
SCHEMBL7511855 0.70 KMT2A (0.48) ALDH1A1HTTXBP1KMT2A
SCHEMBL7497632 0.69 LTA4H (0.44) ALDH1A1HTTXBP1NPC1RAB9A
SCHEMBL19652242 0.68 CNR1 (0.38) ALDH1A1HTTXBP1RAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 — — US claimed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 — — EP claimed
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS LABORATOIRE BIODIM (FR) 2012-01-26 — — US disclosed
EP-2196453-A1 Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents Cellvir (FR) 2010-06-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022054-A1 NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS HAVCR2, MAVS, EIF2AK2 ALDH1A1 455/4885HTT 2001/4885XBP1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback